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Abstract
Background: SK Hep-1 cells (SK cells) derived from a patient with liver adenocarcinoma have been considered a human
hepatoma cell line with mesenchymal origin characteristics, however, SK cells do not express liver genes and exhibit liver
function, thus, we hypothesized whether mesenchymal cells might contribute to human liver primary cancers. Here, we
characterized SK cells and its tumourigenicity.
Methods and Principal Findings: We found that classical mesenchymal stem cell (MSC) markers were presented on SK cells,
but endothelial marker CD31, hematopoietic markers CD34 and CD45 were negative. SK cells are capable of differentiate
into adipocytes and osteoblasts as adipose-derived MSC (Ad-MSC) and bone marrow-derived MSC (BM-MSC) do.
Importantly, a single SK cell exhibited a substantial tumourigenicity and metastatic capacity in immunodefficient mice.
Metastasis not only occurred in circulating organs such as lung, liver, and kidneys, but also in muscle, outer abdomen, and
skin. SK cells presented greater in vitro invasive capacity than those of Ad-MSC and BM-MSC. The xenograft cells from
subcutaneous and metastatic tumors exhibited a similar tumourigenicity and metastatic capacity, and showed the same
relatively homogenous population with MSC characteristics when compared to parental SK cells. SK cells could unlimitedly
expand in vitro without losing MSC characteristics, its tumuorigenicity and metastatic capacity, indicating that SK cells are
oncogenic MSC with enhanced self-renewal capacity. We believe that this is the first report that human MSC appear to be
transformed into cancer stem cells (CSC), and that their derivatives also function as CSCs.
Conclusion: Our findings demonstrate that SK cells represent a transformation mechanism of normal MSC into an enhanced
self-renewal CSC with metastasis capacity, SK cells and their xenografts represent a same relative homogeneity of CSC with
substantial metastatic capacity. Thus, it represents a novel mechanism of tumor initiation, development and metastasis by
CSCs of non-epithelial and endothelia origin.
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Introduction
Carcinomas are a heterogeneous population of a series of cells
with different phenotypes; however, the origin of many cancers
remains unknown. Human liver carcinoma is the fifth most
common cancer worldwide [1], and there are two major
nonexclusive hypotheses of the cellular origin of the liver cancers:
that they derive from stem cells due to maturation arrest or from
dedifferentiation of mature cells. Phenotypically liver cancers can
be divided into well-, moderate-, and poorly-differentiated
carcinomas, and liver-specific genes can be detected in well- and
moderately-differentiated liver cancer cells, indicating that these
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110744
cancers originated from hepatocytes and cholangiocytes; however,
liver specific genes cannot be detected in poorly-differentiated liver
cancer cells, suggesting that these cancers might originate from
other cell types rather than hepatocytes and cholangiocytes. A
third possibility has also been suggested for rodent and human
hepatic malignancies: that bone marrow derived cells may
incorporate into benign or malignant liver tumors [2] or actually
initiate tumor development [3]. In adult liver, 78% of the cells are
hepatocytes; and the majority of non-hepatocytes are thought to
be cholangiocytes [4], sinusoidal endothelia cells, Kupffer cells,
hepatobiliary stem/progenitor cells, hepatic stellate cells, myofi-
broblasts, and pit cells [5–9]. They are implicated in the
physiological and pathophysiological process of liver regeneration,
injury and repair. In humans, besides hepatocytes and cholangio-
cytes, only endothelia cells has been reported to be the origin of
human liver carcinomas [10]; i.e. the SK Hep-1 (SK) cell line. SK
cell is a human cell line derived from a patient with liver
adenocarcinoma in 1971 [11], and it has been reported to be of
endothelia origin with mesenchymal characteristics in 1992 [10].
In our study, we found that the morphology, the tubular
formation, and the expression of vimentin (mesenchymal origin)
in SK cells are the same as in previous reports [10,12]; however,
our investigation further revealed that SK cells did not CD31, a
typical endothelial marker, importantly, endothelia cells originate
from mesenchymal origin [13]. Thus, we hypothesize whether SK
cells represent a kind of mesenchymal cell type, and demonstrate
whether mesenchymal cells contribute to human primary liver
cancer. In this study, we characterized SK cells, and found that
SK cells exhibited an oncogenic mesenchaymal stem cell line with
a great metastatic capacity.
Materials and Methods
Cell lines and cell culture
SK Hep-1 cell, a hepatoma cell line, was purchased from
ATCC (www.atcc.org); adipose-derived mesenchymal stem cells
(MSC-ad) and bone marrow-derived mesenchymal stem cells
(MSC-BM) were purchased from ScienCell Research Laboratories
(www.sciencellonline.com). The cell culture conditions for growing
and expanding these line cells were per the manufacturers
instructions.
Flow cytometry analysis for surface markers
The immunophenotypic characterizations of SK cells, MSC-ad,
MSC-BM, and the re-cultured cells from the isolation of tumor
xenografts and metastatic tumors were performed by flow
cytometry employing 22 PE conjugated antibodies: CD90 (Thy-
1 cell surface antigen), CD44, CD73 (NT5E, 59-nucleotidase),
CD71 (Transferrin receptor protein 1 (TfR1)), CD105 (endoglin,
ENG), CD166 (activated leukocyte cell adhesion molecule,
ALCAM), CD29 (integrin, beta-1, ITGB1), CD106 (vascular cell
adhesion molecule 1, VCAM1), CD49d (integrin alpha subunit),
CD146 (melanoma cell adhesion molecule, MCAM), CD133
(Prominin 1, PROM1), CD13 (Aminopeptidase N), CD54 ICAM-
1 (Intercellular Adhesion Molecule 1, ICAM-1), CD9, CD10
(membrane metallo-endopeptidase), ABC (major histocompatibil-
ity complex (MHC) class I antigen), HLA DR (major histocom-
patibility complex (MHC) class II antigen), and Alkaline
phosphatase (ALP), CD31 (endothelia cell marker), CD34 and
CD45 (hematopoietic markers). The cells were stained as
previously described [14]; all antibodies used are listed in Table
S1.
Differentiation capacity of SK cells
We evaluated the potential of SK cells, MSC-ad, and MSC-BM
to differentiate into adipocytes and osteocytes. The differentiation
and staining with red oil R and alizarin red S was performed as
previously described [15]. ALP activity was assessed by NBT/
BICP staining (Roche).
The generation of cDNA
RNA was extracted from the SK cells, xenograft cells, as well as
undifferentiated and differentiated MSC cells using the Qiagen
mini RNA kit, and cDNA was generated as previously described
[14]. All primers/probes used are listed in the Table S2.
Tumorigenicity of SK cells
SK cells were injected into 8–10 weeks, female NOD/SCID/
IL2rg mice (Jackson Laboratory) by subcutaneous injection of 1,
10, 100, 500, 1,000, 5,000, or 10,000 cells. The re-cultured cells
from primary subcutaneous tumor and metastatic tumors
produced by the injection of parental SK cells were also injected
into the same mouse models with 10 and 100 cells. The small
number of cells (1 and 10) was mixed with 30% of Matrigel (BD
Sciences) for the purpose of avoiding to lose cells during
preparation and transplantation [16]. Surgical procedures for
transplantation and monitoring the tumor formation and subse-
quent tumor collection were approved by the Animal Care and
Use Administrative Advisory Committee of the University of
California Davis.
The isolation and re-culture of the tumor xenograft cells
The tumors xenografts were harvested and cut into small piece
under sterile conditions, and treated with dispase (1 mg/ml) and
collagenase type IV (1 mg/ml), and incubated at 37C for 20 min,
then the tumor tissue was homogenized with a serological pipette,
and supernatants were collected. The remaining tissue was treated
with the same solution for an additional 2–4 times until almost all
tissue was digested. The supernatants were spun at 300 g for
5 min, the cell pellet was re-suspended with MEM medium after
discarding the supernatant and was treated with fixative-free lysing
solution (www.invitrogen.com) for 10 min in the dark to destroy
the blood cells, then filtered with a 100 um cell strainer and spun
again. Finally the cell pellet were re-suspended, and re-cultured
with MEM (parental SK cell culture condition).
Histological assay of xenografts
Primary xenografts and organ tissue with metastatic tumor
xenografts were collected and fixed with 10% formalin, and used
for hematoxylin and eosin staining (H&E stain).
In vitro invasion assay
In vitro migration and invasion was performed using a
basement membrane-based invasion assay (Cell Biolabs, Inc).
100,000 SK cells or MSC-ad or MSC-BM were cultured in a 24-
well size transwell containing growth medium with low serum (2%
of FBS), while the bottom wells were filled with normal growth
medium containing 10% of FBS. After 24 hours culturing, non-
invasive cells were removed, and invasive cells that passed through
the basement membrane were stained and imaged. In a parallel
experiment, the invasive cells were stained and quantified by
measuring OD 560 nm values. 20000, 40000, 60000, 80000, and
100000 SK cells and MSC were seeded in the bottom well, and
stained and quantified as a standard curve. The procedures of the
invasion assay were performed per the manufacturer’s instructions.
SK Hep-1 Cells/Oncogenic MSC with Metastatic Capacity
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Statistics
All data were summarized as means 6 SEM from at least three
independent measurements. An unpaired Student t test was used
to analyze the data. p,0.05 was considered statistically significant.
Results
SK cells exhibited an MSC phenotype
We compared surface markers of SK cells to mesenchymal stem
cells isolated from adipose and bone marrow (MSC-ad, MSC-
BM). We found that classical MSC markers, such as CD90, CD44,
CD73, CD71, CD105, CD146, CD166, CD29, CD13, CD9,
CD10, HLA ABC, and ALP were also present on SK cells
(Figure 1A, Figure S1); however, CD106 was almost absent in SK
cells. Hematopoietic markers, CD34, and CD45, and endothelia
marker CD31, were negative in SK cells, MSC-ad and MSC-BM
(data not shown). Expression levels of MSC markers CD73, CD44,
CD90, CD105, CD166, a-SMA, and the mesenchymal origin
marker, vimentin, did not exhibit significant biological difference
among the three cell type (Figure 1B).
Adipogenic and osteogenic differentiation of SK cells
After culturing with adipogenic or osteogenic differentiation
medium for 2 weeks, SK cells were differentiated into adipocytes
and osteoblasts, with a similar differentiation pattern as MSC-ad
and MSC-BM do, thereby confirming its MSC-like characteristics.
Adipogenic differentiation was evidenced by Red oil R staining,
whereas Alizarin red S staining confirmed the accumulation of
calcium deposits, a characteristic of osteogenic cells, in differen-
tiated SK cells, MSC-ad and MSC-BM (Figure 2). ALP, an
osteogenic marker, was also expressed by these three cell types
under osteogenic differentiation medium for 2 weeks, as deter-
mined by NBT/BICP staining (Figure 2). Expression of four
adipogenic genes, C/EBP a, C/EBP b, PPAR-c, and fatty acid
binding protein 4 (FABP4), were up-regulated in these three cell
types under adipogenic differentiation medium (Figure 3A), and
two osteogenic genes, response gene to complement 32 (RGC32)
and collagen 1A1, were highly expressed under osteogenic
differentiation condition (Figure 3B). On the other hand, the
expression of three major MSC markers, CD73, CD90, and
CD105, was decreased in all three cell types under both
differentiation conditions (Figure 3A and B).
Tumourigenicity and metastasis of SK cells
Highly immunodeficient mice, NOD/SCID/IL2rg mice were
used to evaluate the tumorigenic and metastatic potential of SK
cells by us. What surprised us was that as few as 10 SK cells caused
tumors in over 96% of injected mice, and even a single cell
generated tumors in 10 of 28 injected mice (Table 1). The time
period of the tumor formation by injection with a single cell did
not show significant difference when compared to higher cell
numbers, indicating that SK cells are extremely tumorigenic in
NOD/SCID/IL2rg mice. The tumors invaded into muscles
during formation and growth; thus, even though the actual tumor
size was rather big, the tumor appeared to be smaller. Only after
the skin was excised and the tumors were exposed, then the real
size of the tumors could be observed (Figure S2A–D). Even
sometimes mice were indicated to have the tumors by the fact that
mouse back legs could not stand and lost partial function. The
mice significantly lost weight within 2 months after injection of SK
cells, the average weight of the mice was 18.360.73 g in the range
of 22.22 g to 15.58 g when they were sacrificed. The interesting
finding was that the tumors were widely metastatic, even in the
mice injected with a single cell, although the extent of the
metastases depended on the number of injected cells within the
period of experiments. A few organs were involved in the mice
with injection of a single cell, multiple organs had metastases in the
mice with injection of ten cells, and widely metastatic lesions
occurred in the mice with injection of 100 or more cells (Table 1,
Figure 4, Figure S2). These tumors had a sarcomatous appearance
(white color) lacking significant angiogenesis (Figure 4, Figure S2D
and E). Multiple organs were metastated in all mice, and
metastatic tumors were found in livers and lungs in all treated
mice (Figure 4, Figure S2F–I). The third frequent metastated
organs were kidney (Figure 4D and E) and up-ureters (Figure 4E,
arrow), then another organs with metastatic tumors were spleen
(Figure 4D), pancreases (Figure 4F, arrow), joint at chest and front
leg (Figure 4G), outer peritoneum (abdomen) (Figure 4H), and
Figure 1. Characterization and comparison of SK cells with
mesenchymal stem cells. A, flow cytometry was employed to detect
classical mesenchymal stem cell (MSC) markers in three cell types, SK
Hep-1 cells (SK cells), adipose-derived MSC (MSC-ad), and bone marrow-
derived MSC (MSC-BM). B, expression of MSC markers, vimentin (a
mesodermal origin marker), and alpha smooth muscle actin (a-SMA)
was measured by quantitative PCR in three cell types. Abbreviations:
HLA ABC, major histocompatibility complex (MHC) class I antigen; HLA
DR, MHC class II antigen; ALP, Alkaline phosphatase.
doi:10.1371/journal.pone.0110744.g001
SK Hep-1 Cells/Oncogenic MSC with Metastatic Capacity
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skin (non-injection site) (Figure 4I, arrow). Metastatic tumors were
also found in colon, uterus and ovaries. H and E staining reveals
that the histological and pathological features of primary
subcutaneous tumor cells (Figure 5A), metastatic tumor cells
(arrow) in liver (Figure 5B), lung (Figure 5C), pancreas (Fig-
ure 5D), kidney (Figure 5E), spleen (Figure 5F), colon (Figure 5G),
uterus (Figure 5H), and ovary (Figure 5I), and the tumors
consisted of spindle-like shaped cells with ovoid or elongated
nuclei containing 2 or more nucleoli per nucleus (A–I), similar to
those formed in nude mice [17]. The details of the histological and
pathological features of these primary and metastatic tumor cells
were provided in Figure S3–S5.
Re-cultured cells of primary and metastatic tumors and
serial transplantation
The primary tumors produced by the subcutaneous injection,
and metastatic tumors in lung and liver were collected and the cells
from these tumors were isolated and re-cultured. The morphology
of these cells was the same as those of parental SK cells
(Figure 6A–D), and flow cytomery results showed that the
percentage of classic MSC surface markers in these isolates are
very similar to those in parental SK cells (Figure 6E, Figure 6S),
but HLA DR were slightly decreased in isolates of livers and lungs.
Expression of major MSC markers were not significantly changed
(Figure 6F). These isolates from SK xenografts (primary and
metastatic tumors) were subcutaneously injected into mice, and
subcutaneous tumor formation and metastases occurred as similar
to the parental SK cells (Table 1).
In vitro invasiveness
An in vitro invasion assay showed that SK cells had greater
migration and invasion capacity when compared to MSC-ad and
MSC-BM, a well described invasive cell type. Large number of SK
cells passed the basement membrane 24 hours under low FBS
conditions, as determined by microscopy after staining (Fig-
ure 7A–C). A quantitative assay showed that over 75% of SK cells
migrated and went through the membrane within 24 hours,
whereas 40% of MSC-ad and MSC-BM passed the membrane
during the same period (Figure 7D), this great migration and
invasion capacity might explain why mice had widely metastatic
lesions after the in vivo injection of the SK cells.
Discussion
We have determined that SK Hep-1 cells expressed almost all
MSC markers, such as CD9, CD10, CD13, CD29, CD49d,
CD54, CD71, CD73, CD146, CD166, CD90, CD44, CD105,
HLA-ABC, and alkaline phosphatase (ALP) [18,19]. Although
MSC and endothelial cells share some surface markers, endothelial
cells cannot be differentiated into adiopogenic and osteogenic
lineages, and our results demonstrated that SK cells could be
differentiated into these two cell lineages, which is the cardinal
property of MSC. SK cells expressed almost all MSC genes, but
did not express albumin or alpha fetoprotein (liver lineage),
myogenic factor 5 (MYF5), myogenin (MYOG) and desmin
(myoblast lineage), glial fibrillary acidic protein (GFAP, hepatic
stellate cell lineage), CK14, and CK17 (myoepithelia cell lineage),
Figure 2. Differentiation of three cell types into adipocytes and
osteoblasts. A, SK cells, adipocyte-derived MSC (MSC-ad), and bone
marrow-derived MSC (MSC-BM) were used for the differentiation. B, the
three cell types were differentiated into adipocytes determined by Oil
Red R staining. C, the three cell types were differentiated into
osteoblasts determined by Alizarin Red S staining. D, alkaline
phosphatase staining was performed after the osteoblast differentia-
tion. Magnifications: 100X
doi:10.1371/journal.pone.0110744.g002
Figure 3. Gene expression patterns in differentiated SK cells,
MSC-ad and MSC-BM. A and B, expression levels of adipocyte genes,
C/EBPa, C/EBPb, PPAR-c, and FABP4 (A), osteoblast genes, RBC32 and
COL1 (B), and MSC genes, CD73, CD90, and CD105 (A and B) were
measured by quantitative PCR in differentiated SK cells, MSC-ad and
MSC-BM at day 15 after differentiation. Abbreviations: SK, SK Hep-1
cells; MSC-ad, adipocyte-derived MSC; MSC-BM, bone marrow-derived
MSC; FABP4, fatty acid binding protein 4; RBC32, response gene to
complement 32; COL1, collage 1A1.
doi:10.1371/journal.pone.0110744.g003
SK Hep-1 Cells/Oncogenic MSC with Metastatic Capacity
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or CD34, and CD45 (hematopoietic cell lineage). von Willebrand
factor (vWF) was slightly expressed in SK cells (ct values were
between 32–35 as determined by quantitative PCR); however,
other endothelial cell markers, CD34, CD31, CD144, E-selectin,
and CD106/ICAM-1, were not detected in SK cells. SK cells have
been thought to be endothelial in origin with the major evidence
being the presence of Weibel-Palade bodies and tubular formation
by the cells [10]. If SK cells were truly of endothelial origin, it is
possible to speculate that oncogenically transformed endothelial
progenitors might be transdifferentiated into mesenchymal cells
after the oncogenic hit, similar to this occurrence during normal
embryonic development [13]. However, a more likely explanation
of the data suggests the possibility that SK cells might originate
from pericyte/perivascular cells. Pericytes and endothelial pro-
genitor cells (EPC) share many properties; for example, they come
from mesenchymal origin, share many surface markers, form
tubular structures in vitro, and this tubular formation can be
inhibited by the same inhibitors [20]. Importantly, pericytes can
Figure 4. Histological features of primary tumors and meta-
static tumors. A, the primary tumors (human xenografts) were formed
by the subcutaneous injection of SK cells, and these tumors had a
sarcomatous appearance (white color) lacking angiogenesis. B-I,
metastatic tumors were found in different organs, such as liver (B),
lung (C), spleen, kidney and ureter (D), kidney and ureter (arrow) (E),
kidney, liver, and pancreas (arrow) (F), joint at chest and front leg (G),
outer peritoneum (H), under skin (arrow) (I) (non-injection site).
doi:10.1371/journal.pone.0110744.g004
Figure 5. Pathological and histological features of primary
tumors and metastatic tumors. A-I, the primary tumors (human
xenografts) were formed by the subcutaneous injection of SK cells, and
were metastasized to different organs. H and E staining reveals that the
histological and pathological features of primary subcutaneous tumor
cells (A), metastatic tumor cells (arrow) in liver (B), lung (C), pancreas (D),
kidney (E), spleen (F), colon (G), uterus (H), and ovary (I). The tumors
consisted of spindle-like shaped cells with ovoid or elongated nuclei
containing 2 or more nucleoli per nucleus (A–I). Magnifications: 200 x
doi:10.1371/journal.pone.0110744.g005
Table 1. Tumourigenicity and metastasis of SK cells and its xenograft cells.
Injected cell types No. of injected cells No. of mice with tumors Days of tumor formation Metastasis
SK cells 10,000 6/6 33–42 Yes
SK cells 5,000 6/6 37–45 Yes
SK cells 1,000 6/6 37–45 Yes
SK cells 500 6/6 40–46 Yes
SK cells 100 6/6 40–46 Yes
SK cells 10 27/28 40–53 Yes
SK cells 1 10/28 49–64 Yes
Isolates-skin 100 6/6 35–42 Yes
Isolates-liver 100 6/6 35–42 Yes
Isolates-lung 100 6/6 35–40 Yes
Isolates-skin 10 6/6 39–50 Yes
Isolates-liver 10 6/6 41–53 Yes
Isolates-lung 10 6/6 43–54 Yes
The tumourigenicity was evaluated by the injection of SK cells into NOD/SCID/IL2rg mice, and serial transplantation was also performed by the injection of the tumor
xenograft cells isolated from primary and metastatic tumors. The tumors were formed, and metastasis was widely found in the mice.
doi:10.1371/journal.pone.0110744.t001
SK Hep-1 Cells/Oncogenic MSC with Metastatic Capacity
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give rise to MSC in vivo and in vitro [21]. Whether SK cells
originated from endothelia cells, or pericytes, or from another cell
type of mesenchymal origin is under further investigation.
SK cells were isolated from a patient with liver adenocarcinoma
[11], and designated as a hepatoma cell line. In our study, the
tumors could be formed within two months after subcutaneous
injection of as few as one SK cell in NOD/SCID/IL2rg mice.
Normally a single cancer cell does not have the capacity to form
tumors, even in highly immnuodeficient mice, only cancer stem
cells have this capacity. Importantly, the time period of tumor
formation by a single cell did not differ significantly when
compared to tumors formed by the injection with 10,000 cells,
thus suggesting that SK cells are extremely tumorigenic. Only 10
of 28 mice injected with one cell formed tumors, and the reason
may well be because the cell was lost during transplantation and
did not actually get into the mouse, or the cell was dead during the
preparation and transplantation. Wide-spread metastases were
found in the mice, even with a single cell subcutaneously injected,
demonstrating aggressive migration and invasion properties which
are often associated with cells of mesenchymal origin. This
property was confirmed by in vitro invasion assay which showed
that over 75% of SK cells could invade base membrane of
transwells within 24 h. The cells isolated from primary subcuta-
neous tumors, or from the metastatic tumors of livers and lungs,
did not change their gene expression pattern and MSC phenotype,
tumorigenicity and metastatic capacity. Therefore, the entire SK
cells population appears to function as a cancer stem cell line with
highly tumorigenic and metastatic capacities, and this property
can be maintained in in vitro culture and in vivo by serial
transplantations.
Normally MSC can maintain multipoptency and their pheno-
type for a short period at low passage after isolation, and they will
lose this property and differentiate or transdifferentiate into other
cell types after long-term culture at higher passages in vitro. SK
cells appear to function as oncogenically transformed MSC with
enhanced self-renewal and proliferation, because they can be
Figure 6. Characterization of isolates from primary tumors and metastatic tumors. A–D, parental SK cells (A), re-culture of subcutaneous
primary tumors (B), re-culture of metastatic tumors in liver (C) and lung (D). E, classical mesenchymal stem cell (MSC) markers were detected and
measured in three isolates employing flow cytometry. F, expression of MSC markers, vimentin (a mesodermal origin marker), and alpha smooth
muscle actin (a-SMA) was measured by quantitative PCR in three isolates. Abbreviations: HLA ABC, major histocompatibility complex (MHC) class I
antigen; HLA DR, MHC class II antigen; ALP, Alkaline phosphatase. Magnifications: 100X
doi:10.1371/journal.pone.0110744.g006
SK Hep-1 Cells/Oncogenic MSC with Metastatic Capacity
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unlimitedly expanded and maintained in culture without losing
multipotency and changing its phenotype. Although the concept of
cancer stem cells is still controversial, recent reports indicate that
CSCs do exist in tumors employing mouse models [22–26].
However, the origin and formation of cancer stem cells remains
elusive, and some reports indicate that cancer stem cells may
derive from normal stem cells by acquiring an oncogenic hit [27–
29]. For example, a recent paper has suggested that liver cancer
stem cells are derived from the enhanced self-renewal of facultative
liver stem cells [30]. Although cancer stem cells/tumor-initiating
cells have been isolated and expanded in culture [26,31], CSCs
have not been shown previously to suscessfully be expanded and
be maintained in vitro for long term culture. Thus, we believe that
this is the first report to show that SK cells appear to exhibit the
characteristics of transformed normal MSC by acquiring en-
hanced self-renewal capacity after an oncogenic hit, and further-
more, they appear to have transformed into a cancer stem cells
line which can be expanded and maintained in vitro and in vivo
for a prolonged period without losing MSC phenotype, tumour-
iogenicity, and metastatic capacity.
The primary tumors or the xenografts produced by cancer stem
cells or tumor-initiating cells represent heterogeneous population
with different cell types, only a small number of cells remain
cancer stem cell property. However, the subcutaneous tumors or
metastatic tumors produced by a single SK cells or 10,000 SK cells
exhibited a relative homogenous population with MSC phenotype
which is the same with parental SK cells. Parental SK cells with
MSC characteristics did not differentiate into other cell lineages
such as adipose, osteoblast, or chondrocytes during the tumor
formation or metastasis after injection into mice. The formation of
the subcutaneous tumors and metastatic tumors is just prolifera-
tion or self-renewal of SK cells in vivo as they do in vitro. This
phenomenon or mechanism is apparently different from those of
epithelial cell- and endothelial cell-based tumor/cancer formation
and metastasis.
In summary, parental SK cells and their xenografts exhibit same
oncogenic MSC characteristics with highly metastatic capacity,
even a single SK cell has such tumorigenicity and metastatic
capacity, moreover, parental SK cells and their xenografts present
a relative homogeneity with the same phenotype. SK cells’
mesenchymal origin and mesenchymal phenotype demonstrated
that mesenchymal cell type contributed to the liver carcinoma of
the patient which SK cells was derived from. Therefore, it
represents a novel mechanism of tumor initiation, development
and metastasis by cancer stem cells of non-epithelial and
endothelia origins.
Supporting Information
Figure S1 Characterization of surface markers of SK
Hep-1 cells and mesenchymal stem cells. Flow cytometry
was employed to detect and measure classical mesenchymal stem
cell (MSC) markers in three cell types, SK Hep-1 cells, adipose-
derived MSC (MSC-ad), and bone marrow-derived MSC (MSC-
BM).
(JPG)
Figure S2 The tumor growth and metastasis character-
istics. A, the tumor appearance before open of the skin when the
mouse was sacrificed, and the tumor apparently looked small. B,
the tumor appearance after open of the skin before the isolation,
the tumors grew invasively. C, the tumors were isolated from the
mice, and embedded holes were left after the tumors were
removed. D, this tumor sizes:.0.5 cm (height) 61 cm (width)
61.5 cm (length). E, the average tumor sizes were $0.5–1.0 cm
(height)61.0–1.5 cm (width)61.5–2.0 cm (length) after isolation.
F, Metastatic tumors were found in multiple organs in single
mouse, for example, metastatic tumors were found in lung and
liver in one mouse (left), and metastatic tumors were also found in
kidney and up-ureter in the same mouse. Arrow indicates normal
ureter (right). G, lungs, liver, and kidneys with metastatic tumors
Figure 7. In vitro invasion assay A–C, the invasion of stained adipose-derived msenchymal stem cells (A), bone marrow-derived mesenchymal stem
cells (B), and SK cells (C), were evaluated from transwells at 24 hours after culturing under low serum. D, based on the standard curve, the number of
invading cells was quantitated. Magnifications: 1006 (A–D).
doi:10.1371/journal.pone.0110744.g007
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were isolated from this single mouse shown in F. H and I:
metastatic tumors were found in livers (H) and lungs (I) of all
treated mice.
(JPG)
Figure S3 Histological features of primary tumors and
metastatic tumors. A–C, H and E staining reveals that the
histological and pathological features of primary subcutaneous
tumor cells (A), metastatic tumor cells (arrow) in liver (B), and lung
(C). Magnifications: 40 x.
(JPG)
Figure S4 Histological features of metastatic tumors.
A–C, H and E staining reveals that the histological and
pathological features of metastatic tumor cells (arrow) in pancreas
(A), kidney (B), and spleen (C). Magnifications: 40 x.
(JPG)
Figure S5 Histological features of metastatic tumors.
A–C, H and E staining reveals that the histological and
pathological features of metastatic tumor cells (arrow) in colon
(A), uterus (B), and ovary (C). Magnifications: 40 x.
(JPG)
Figure S6 Characterization of surface markers of
primary tumor cells and metastatic tumor cells. Flow
cytometry was employed to detect and measure classical
mesenchymal stem cell (MSC) markers in three isolates from the
primary tumors (Skin-isolate) produced by the subcutaneous
injection, and metastatic tumors in liver (Liver-isolate) and lung
(Lung-isolate).
(JPG)
Table S1 List of antibodies used. Abbreviations: ALP,
Alkaline phosphatase; PE, phycoerthrin; HLA ABC, human major
histocompatibility complex (MHC) class I, human leukocyte
antigens, A, B, C; HLA DR, MHC class II cell surface receptor;
FC, flow cytometry.
(DOC)
Table S2 Information of primers and probes used for
qPCR. Abbreviations: GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; AFP, alpha fetoprotein; a-SMA, alpha smooth
muscle actin; FABP4, fatty acid binding protein 4; RGC32,
response gene to complement 32 protein; COL1A1, Collagen,
type I, alpha 1; MYF5, Myogenic factor 5; MYOG, Myogenin or
myogenic factor 4; GFAP, Glial fibrillary acidic protein; E-SELE,
E-selectin; vWF, Von Willebrand factor; C/EBP, CCAAT-
enhancer-binding protein; PPAR, Peroxisome proliferator-activat-
ed receptor.
(DOC)
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